Considering that patients who develop symptomatic hepatitis D may progress into cirrhosis, liver failure and hepatocellular carcinoma, research for an adequate therapeutic regimen and for new and more effective drugs, with less side-effects, and lower costs may be considered cost-effective.
Hepatitis D cost-effectiveness of therapy
Hepatitis B cost-effectiveness of therapy
Hepatitis C cost-effectiveness of therapy
Hepatitis E cost-effectiveness of therapy
Hepatitis survival guide
Hepatitis E primary prevention
Hepatitis B diagnostic criteria
Hepatitis C classification